Zacks Investment Research
13 Oct 2026, 12:47 UTC · 2h ago
Johnson & Johnson (JNJ) Q3 Earnings Surpass Estimates
Impact · against what's priced in
The Q3 results are largely noise as the modest earnings beat is offset by a revenue miss and a year-over-year EPS decline. The results fail to provide the acceleration in growth needed to support the valuation targets the market is currently discounting.
- JNJ−0.20
Challenges what's priced in
- The price assumes
Can Innovative Medicine and MedTech collectively accelerate revenue growth from the delivered 6% toward the 13.1% the price requires
The 0.15% revenue miss and a 7.5% year-over-year drop in adjusted EPS ($2.59 vs $2.80) suggest the company is struggling to find the growth acceleration the current price requires.
What JNJ's price assumes · Sep 3
Search tags
